MARKET

IMMP

IMMP

Immutep
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.690
-0.130
-4.61%
After Hours: 2.660 -0.03 -1.12% 19:10 02/25 EST
OPEN
2.840
PREV CLOSE
2.820
HIGH
2.840
LOW
2.640
VOLUME
335.19K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
0.5300
MARKET CAP
131.17M
P/E (TTM)
-1.1574
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Immutep Price Target Raised 8.3% to A$0.65/Share by Bell Potter
Immutep Price Target Raised 8.3% to A$0.65/Share by Bell Potter
Dow Jones · 02/07 22:26
Global Drugs For Gram-Positive Bacterial Infections Market Analysis 2021: Industry Size, CAGR with Geographical Segmentation, Business Challenges, and Growing Demand Status Forecast to 2025
Feb 04, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Drugs For Gram-Positive Bacterial...
The Express Wire · 02/04 06:52
Investors Who Bought Immutep (ASX:IMM) Shares Three Years Ago Are Now Up 84%
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Simply Wall St. · 02/02 18:24
Investors Who Bought Immutep (ASX:IMM) Shares Three Years Ago Are Now Up 84%
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Simply Wall St. · 02/02 18:24
Investors Who Bought Immutep (ASX:IMM) Shares Three Years Ago Are Now Up 84%
Simply Wall St. · 02/02 18:24
Investors Who Bought Immutep (ASX:IMM) Shares Three Years Ago Are Now Up 84%
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Simply Wall St. · 02/02 18:24
Immutep's lead candidate efti moves forward in mid-stage COVID-19 study
Immutep's (IMMP) gains 6% in premarket, after independent Data and Safety Monitoring Board ((DSMB)) has recommended Phase 2 study evaluating company's lead product candidate eftilagimod alpha (efti) in COVID-19, to advance with enrollment for the randomize...
Seekingalpha · 01/27 14:20
AMC, BB, BBBY and GME among notable premarket gainers
AMC Entertainment Holdings (AMC) +240%.Koss Corporation (KOSS) +117%.Express (EXPR) +91%.GameStop (GME) +55%.Vislink Technologies (VISL) +22% as shipping of Satellite communications equipment begins.Revlon (REV) +16%.J.Jill (JILL) +17%.Accelerate Diagnosti...
Seekingalpha · 01/27 13:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMMP. Analyze the recent business situations of Immutep through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMMP stock price target is 6.47 with a high estimate of 8.17 and a low estimate of 5.11.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 680.10K
% Owned: 1.39%
Shares Outstanding: 48.76M
TypeInstitutionsShares
Increased
2
96.02K
New
7
61.63K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Non-Executive Chairman
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Non-Executive Director
Grant Chamberlain
  • Dividends
  • Splits
  • Insider Activity
No Data
About IMMP
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.